Two cancer drugs prevent, reverse type 1 diabetes, study shows

November 18, 2008

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco. The drugs – imatinib (marketed as Gleevec) and sunitinib (marketed as Sutent) – were found to put type 1 diabetes into remission in 80 percent of the test mice and work permanently in 80 percent of those that go into remission.

The findings may offer a new weapon against this autoimmune disease, formerly called juvenile-onset diabetes, for which few drugs have been developed to address the underlying causes, the lead scientists say.

"There are very few drugs to treat type 1 diabetes, especially after disease onset, so this benefit, with a drug already proven to be safe and effective in cancer patients, is very promising," said Jeffrey Bluestone, PhD, director of the Diabetes Center at UCSF and an expert in the study of autoimmunity. "The fact that the treated mice maintained normal blood glucose levels for some time after the drug treatment was stopped suggests that imatinib and sunitinib may be 'reprogramming' their immune systems in a permanent way."

Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor of the Diabetes Center at UCSF and a senior author on the paper.

Both drugs treat cancer by inhibiting a small subset of the more than 500 tyrosine kinases, which are enzymes that modify cells' signaling proteins through a simple biochemical change. Kinases are ubiquitous agents of cell growth and proliferation, and are also involved in many diseases such as inflammation and cancer. In the immune system, tyrosine kinases are thought to be key to nearly every aspect of immunity, from the signaling that initiates a response by the immune system's T and B cells to later stages of inflammation that can cause tissue damage.

Because type 1 diabetes is caused by an autoimmune response that destroys insulin-secreting cells in the pancreas, the scientists sought to determine if one or more of the tyrosine kinases blocked by the two cancer drugs might also be responsible for the destructive inflammation in the pancreas. If so, the drugs might be promising candidates to treat diabetes.

Using a well-established mouse model for diabetes, known as the non-obese diabetic (NOD) mouse, they found that treating mice with imatinib or sunitinib before the onset of autoimmune diabetes prevented the development of the disease. Findings showed that the drugs' benefits lasted well after the seven-week treatment. Studies with mice that already had diabetes showed that imatinib put the disease into permanent remission in 80 percent of the mice after only eight to 10 weeks of treatment.

The scientists aimed to determine which of the tyrosine kinases targeted by the two cancer drugs might be responsible for triggering diabetes. To their surprise, a few of the drugs' primary targets did not appear crucial to the diabetes treatment's success.

Instead, they found that the drugs' rapid benefit appears to derive from the ability to block receptors of a tyrosine kinase not known to be implicated in diabetes, an enzyme known as platelet-derived growth factor receptor, or PDGFR. This kinase regulates cell growth and division, and also plays a key role in inflammation in a variety of settings.

"This study opens up a new area of research in the field of type 1 diabetes, and importantly, opens up exciting opportunities for developing new therapies to treat this disease and other autoimmune diseases," said Arthur Weiss, MD, PhD, UCSF professor of rheumatology and a senior author on the paper.

Weiss is the Ephraim P. Engleman Distinguished Professor and chief of rheumatology at UCSF.

The scientists will continue to study the effects of PDGFR in type 1 diabetes and have now applied for funding to perform a safety and efficacy clinical trial in patients.

Source: University of California - San Francisco

Explore further: Long-sought discovery fills in missing details of cell 'switchboard'

Related Stories

Could your smartphone one day tell you you're pregnant?

July 1, 2015

Researchers at the Hanover Centre for Optical Technologies (HOT), University of Hanover, Germany, have developed a self-contained fiber optic sensor for smartphones with the potential for use in a wide variety of biomolecular ...

Topology looks for the patterns inside big data

May 18, 2015

Big data gets much attention from media, industry and government. Companies and labs generate massive amounts of data associated with everything from weather to cell phone usage to medical records, and each data set may involve ...

Recommended for you

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

Quantum Theory May Explain Wishful Thinking

April 14, 2009

(PhysOrg.com) -- Humans don’t always make the most rational decisions. As studies have shown, even when logic and reasoning point in one direction, sometimes we chose the opposite route, motivated by personal bias or simply ...

Why do the majority of people never get cancer?

January 22, 2009

(PhysOrg.com) -- Every year, millions of people are diagnosed with cancer - a remarkably high number. But what about the flipside of those statistics? That is, two out of three people never get cancer, and more than half ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Rain
not rated yet Nov 25, 2008
When you start the clinical trials in patients I would like to participate. I have had type 1 diabetes for 17 yrs and I am 43 yrs old.
Poprough
not rated yet Dec 05, 2008
When you start the clinical trials in patients i would like to be informed. I have an 8 year oild grandchild that has been type 1 sence the age of 18 months. I have lost members of my family to Diabetes and would like to see one of them helped before it comes to lossing another.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.